Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.Donate to our crowdfunder
No information is held centrally and no such assessment has been made by this Department.
Eculizumab is not a licensed treatment for Dense Deposit Disease and well-constructed clinical trials on effectiveness are yet to be carried out. A new policy proposition for its use in treating the disease before a patient has had a kidney transplant will be considered during 2016-17.
There is a published policy on use of this drug for the prevention of recurrence after a patient has had a transplant. A policy on the treatment of C3 glomerulopathy that occurs after a kidney transplant will be considered by the Clinical Priorities Advisory Group (CPAG) at its next meeting. CPAG reviews both patient benefits and cost considerations when making recommendations.